Entering text into the input field will update the search result below

U.K. approves GSK-Vir Bio's COVID-19 antibody treatment which cuts hospitalization/death by 79%

SARS-CoV-2 Coronavirus Variant Omicron B.1.1.529

CROCOTHERY/iStock via Getty Images

  • Britain's drug regulator has approved GlaxoSmithKline (NYSE:GSK) and Vir Biotechnology's (NASDAQ:VIR) antibody based COVID-19 treatment, Xevudy (sotrovimab), for people with mild-to-moderate COVID-19 who are at high risk of developing severe disease.
  • In a clinical trial, a

Recommended For You

Related Stocks

SymbolLast Price% Chg
GSK
--
VIR
--